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What is already known about this subject? 
• Circulating metabolite patterns may serve as early indicators of disease risk. 
• In adults, a branched chain amino acid (BCAA) metabolite pattern is detectable over a 
decade prior to insulin resistance and incident type 2 diabetes. 
• The majority of published studies in children have been cross-sectional, thereby precluding 
inference on temporality between metabolite patterns and conventional metabolic risk 
factors. 
What does this study add? 
• The BCAA and androgen hormone metabolite patterns, both of which were previously 
cross-sectionally associated with excess adiposity and metabolic risk in the study 
population, were related to change in several metabolic biomarkers during ~5 years of 
follow-up (baseline age 6-10 years) in a sex-specific manner. 
• The BCAA pattern was related to a decrease in fasting glucose in boys, and an increase in 
triglycerides in girls.  
• The androgen hormone pattern was associated with a decrease in leptin and an increase in 
C-reactive protein in girls.  
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ABSTRACT  
Objective: To examine associations of two obesity-related metabolite patterns with changes in 
metabolic biomarkers during early adolescence. 
Methods: Using multivariable linear regression, we examined associations of a branched chain 
amino acid (BCAA) and androgen hormone patterns with changes in glycemia (fasting glucose, 
insulin, HOMA-IR), adipokines (leptin, adiponectin), inflammation (C-reactive protein, 
interleukin-6), lipid profile, and blood pressure during ~5 years follow-up among 213 children 
aged 6-10 years at baseline. We adjusted for baseline age, pubertal status, biomarker level, and 
BMI percentile; and age at follow-up. We also tested for interactions with sex and baseline BMI 
percentile. 
Results: Median age at baseline was 7.7 years; 48.8% were boys. In adjusted models, each 1 unit 
of the BCAA pattern corresponded with a 4.82 (95% CI: 0.92, 8.71) mg/dL decrease in fasting 
glucose in boys. In girls, the BCAA pattern was associated with an increase in triglycerides (4.17 
[0.03, 8.32] mg/dL). The androgen pattern was associated with decreased leptin (-2.35 [-4.34,      
-0.35] ng/dL) and increased CRP (0.28 [0.03, 0.54] mg/dL) in girls. These relationships did not 
differ by baseline BMI percentile. 
Conclusions: The BCAA and androgen hormone metabolite patterns are related to changes in 
metabolic parameters in a sex-specific manner during early adolescence.   
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INTRODUCTION 
In the last two decades, prevalence of type 2 diabetes increased by almost a third among 
children and adolescents in the U.S. (1). These trends are alarming, as youth with chronic 
conditions present treatment challenges and will enter adulthood with several years of disease 
duration, and greater risk of early complications (2). Despite population-based efforts to reduce 
risk of metabolic disease via obesity prevention and lifestyle modifications, the need to pair this 
strategy with targeted approaches for high-risk individuals and subgroups was recently 
acknowledged by the Institute of Medicine (3). 
Profiling of circulating metabolites (“metabolomics”) shows promise as one route to 
identifying specific targets for primary prevention. Studies in adults have unveiled distinct 
differences in plasma metabolite composition of persons who are obese vs. lean (4), some of 
which precede development of insulin resistance and type 2 diabetes by over a decade, 
independently of weight status (5). These findings suggest that metabolite patterns have higher 
discriminative capacity than weight or traditional biomarkers to identify persons at risk of type 2 
diabetes earlier on the disease continuum, and that some metabolite patterns may signal risk even 
among individuals who are not overweight/obese.  
Less is known of these relationships earlier in the life course. Despite a handful of recent 
analyses exploring cross-sectional associations of circulating metabolites with conventional 
biomarkers of glycemia in children and adolescents (6-9), only three studies interrogated this 
relationship prospectively: one study followed 17 adolescents in Boston over the course of 18 
months (9), another was a two-year study of 102 Korean boys (10), and a third followed 16 non-
diabetic adolescents from an obesity clinic for 2.3 years (11). The scant literature in youth is 
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problematic given the importance of understanding determinants and etiology of worsening 
metabolic health during early-life for effective prevention.  
Here, we used data from a cohort of children aged 6-10 years at baseline to attain a better 
understanding of biological pathways underlying worsening metabolic health during 
adolescence.  We investigated associations of two previously-characterized metabolite patterns 
related to metabolic risk during mid-childhood (a branched chain amino acid [BCAA] and an 
androgen steroid hormone metabolite pattern (8)) with change in several metabolic biomarkers 
during 5 years of follow-up.  We also aimed to identify and characterize differences in the 
relationships of interest by baseline weight and pubertal status.  
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METHODS 
Study population 
This study includes participants of Project Viva, a pre-birth cohort recruited from a multi-
specialty group practice in Massachusetts (Atrius Harvard Vanguard Medical Associates). 
Details on study design and recruitment are reported elsewhere (12). Children in this analysis are 
a subset of participants in a pilot study that characterized serum metabolites associated with 
obesity and metabolic risk during mid-childhood (age 6-10 years) (8).  Of the 262 participants in 
the pilot study, we considered 253 who attended the early teen research visit (age 11-15 years) 
and provided fasting blood. The final analytic sample included 213 children with data on change 
in any of the metabolic biomarkers of interest. The Institutional Review Board of Harvard 
Pilgrim Health Care approved all study protocols. All mothers provided written informed 
consent and children provided verbal assent.  
Blood collection 
At the mid-childhood (baseline) and early teen (follow-up) research visits, trained 
research assistants (RAs) collected an 8-hour fasting blood sample from the antecubital vein. All 
samples were refrigerated immediately, processed within 24 hours, and stored at -80oC until time 
of analysis.   
Exposure: plasma metabolites  
We carried out untargeted metabolomic profiling in fasting plasma collected during mid-
childhood via a multi-platform mass spectroscopy (MS)-based technique (13-15). Details 
regarding sample preparation and analysis for this population have been published (13-15) and 
are in the Supplemental Material.  
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For statistical analysis, we examined metabolites in the form of a principal component 
analysis (PCA) factor score, henceforth referred to as the branched chain amino acid (BCAA) 
and androgen pattern, both of which were cross-sectionally associated with excess adiposity and 
metabolic risk in this population during mid-childhood (8). We also examined key metabolites 
within each metabolite pattern (i.e., those with a factor loading >|0.5|) as a z-score, centered at 
the median, and scaled to 1 mean absolute deviation (8). 
Outcome: change in metabolic biomarkers during follow-up 
At both the mid-childhood and early teen visits, we used fasting blood to measure plasma 
glucose, ins lin, leptin, adiponectin, C-reactive protein (CRP), and interleukin-6 (IL-6); and 
serum total cholesterol, triglycerides, and high-density lipoprotein (HDL). We calculated low-
density lipoprotein (LDL) using the following equation: LDL = total cholesterol–HDL–
(triglycerides/5), and estimated insulin resistance using the homeostasis model assessment for 
insulin resistance [HOMA-IR= (glucose mg/dL x insulin µIU/mL)/405]. Details on assays for 
laboratory analyses are in the Supplemental Material. We measured systolic (SBP) and 
diastolic blood pressure (SBP) using biannually-calibrated automated oscillometric monitors 
(Dinamap Pro100, Tampa, Florida). RAs recorded BP on the child’s upper arm up to five times 
at one-minute intervals. We used the average of the five measurements for the statistical analysis.   
In addition to examining individual biomarkers, we derived a metabolic syndrome z-
score (MetS z-score) calculated the mean of five age- and sex-specific internal z-scores for waist 
circumference, inverted HDL, natural log (ln)-transformed triglycerides (due to non-normal 
distribution of the original variable), ln-transformed HOMA-IR, and systolic blood pressure. 
This score is modified version proposed by Viitasalo et al. (16). Specifically, we used HOMA-IR 
in lieu of fasting glucose and insulin, as this index has been shown to be a better assessment of 
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glycemic homeostasis in children than glucose or insulin alone (17-19); included HDL and 
triglycerides individually rather than as a ratio given evidence of limited utility of this ratio in 
children (20); and used SBP instead of the average of SBP and DBP since SBP is more reliably 
measured in children and is a stronger predictor of future health (21).  
In the analysis, we focused on change in each biomarker and MetS z-score between the 
two research visits.  
Covariates 
Assessment of covariates, including perinatal and sociodemographic characteristics, and 
child anthropometry and pubertal status are in the Supplemental Material.  
Data analysis 
Step 1. We examined bivariate associations of the BCAA and androgen metabolite pattern factor 
scores (see Perng et al. (8) for details on factor creation) with background and sociodemographic 
characteristics. This step, in conjunction with our knowledge of determinants of metabolic 
health, informed covariate selection. 
Step 2. We investigated relations of the two metabolite patterns, separately, with change in each 
of the biomarkers using multivariable linear regression models that accounted for the child’s age, 
pubertal status, and the biomarker of interest at baseline; and age at follow-up (Model 1). We 
also further accounted for BMI percentile at baseline (Model 2), since weight status is a 
determinant of future metabolic risk (22). Because tests for interactions indicated effect 
modification by sex (P-interaction<0.05), we ran all models separately for boys and girls. We 
used complete case analysis, which resulted in a decreasing sample size with the addition of 
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covariates. To assess for potential bias due to missing data, we examined background 
characteristics across each of the subsamples (Table S1).  
Step 3. To gain insight into biochemical pathways underlying associations of the BCAA and 
androgen patterns with the conventional biomarkers, we further investigated relations of 
individual metabolites with a factor loading >|0.50| in each of the patterns with change in 
biomarkers that were predicted by this pattern in Step 2. In other words, if we detected a 
significant association (P<0.05) between a metabolite pattern and change in a biomarker, we 
further explored associations of individual metabolites within the metabolite pattern with this 
biomarker.  
In all models, we tested for an interaction between the metabolite pattern and baseline 
BMI percentile (continuous) and pubertal status (ordinal summary score). We observed evidence 
of interactions between the BCAA pattern and pubertal status for one of the biomarkers in boys, 
so we evaluated puberty-stratified associations for this biomarker (pre-pubertal vs. pubertal). We 
also carried out sensitivity analyses to assess the impact of further adjustment for covariates that 
were associated with the metabolite patterns in bivariate analysis.  
Because the relationships of interest involve correlated exposures (metabolites on related 
pathways) and outcomes that cluster and track over time (metabolic biomarkers), we did not 
account for multiple comparisons. Instead, we focus on the magnitude and direction of 
associations rather than statistical significance when interpreting results. Additionally, although 
tempo of maturation during follow-up could impact findings, we controlled only for pubertal 
status at baseline and interpreted the estimates as the total effect of the metabolite patterns on 
metabolic risk during follow-up given that change in pubertal status could be on the causal 
pathway, and thus, adjusting for it could introduce bias (23).  
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All models met standard assumptions for multivariable linear regression (linearity of 
exposure/outcome relationship, homoscedasticity of error, normality of residuals). All analyses 
were performed using SAS 9.4 (Cary, NC).  
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RESULTS 
 Median age of the participants at the baseline mid-childhood visit was 7.7 years (range: 
6.7 to 10.6); 48.8% (n=104) were boys. Descriptive statistics on the factor scores, age, BMI, and 
the metabolic biomarkers at the mid-childhood and early teen visits are presented in Table 1.  
 Table 2 shows bivariate associations of the BCAA and androgen factor scores with 
perinatal and sociodemographic characteristics. Children from households with an annual 
income <$70K vs. >$70K had a higher BCAA score (β=0.43, 95% CI: 0.01, 0.85). As we have 
previously shown (8), children of obese women had a higher BCAA score than those whose 
mothers were overweight (β=0.64, 95% CI: 0.06, 1.22) or normal weight (β=0.74, 95% CI: 0.23, 
1.24) prior to pregnancy. Children who were obese at baseline exhibited a higher BCAA score 
than their overweight (β=0.93, 95% CI: 0.29, 1.56) and normal weight (β=1.14, 95% CI: 0.72, 
1.55) counterparts. We observed similar associations for the androgen factor score (Table 2). 
Additionally, children classified as pubertal had a higher score for this metabolite pattern than 
pre-pubertal participants (β=0.60, 95% CI: 0.14, 1.06). 
 Table 3 shows associations of the BCAA pattern at baseline (mid-childhood) with 
changes in the metabolic biomarkers during follow-up (difference between the early teen and 
mid-childhood values). A higher score for the BCAA pattern was associated with a decrease in 
fasting glucose in boys, even after adjusting for age, pubertal status, and fasting glucose at 
baseline; and age at follow-up. Specifically, each 1 unit increment in the BCAA score 
corresponded with a 4.70 (95% CI: 0.93, 8.47) mg/dL decrease in fasting glucose (Model 1). 
This association did not materially change after accounting for baseline BMI percentile (Model 
2: β=-4.97, 95% CI: -8.83, -1.11 mg/dL per 1 unit BCAA score), suggesting that the BCAA 
pattern predicts change in fasting glucose even after accounting for glucose levels and adiposity 
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at baseline. In girls, each 1 unit increment in the BCAA score was associated with a 4.38 (95% 
CI: 0.40, 8.37) mg/dL increase in serum triglycerides levels in Model 1. Adjustment for baseline 
BMI percentile in Model 2 attenuated the estimate by <10% (β= 3.99, 95% CI: -0.13, 8.11 
mg/dL per 1 unit BCAA score). 
 We did not observe any associations of the androgen pattern with change in the metabolic 
biomarkers among boys (Table 4). In girls, a higher score for the androgen pattern corresponded 
with a decrease in leptin (β=-2.39, 95% CI: 4.76, -0.02 ng/dL per 1 unit factor score in Model 1), 
and an increase in CRP (β=0.28, 95% CI: 0.03, 0.54 mg/dL per 1 unit factor score in Model 1). 
These estimates were essentially unchanged after adjustment for baseline BMI percentile in 
Model 2. 
 To obtain a more granular understanding of specific compounds driving the associations 
detected with respect to the factor scores, we further examined relations of key metabolites 
within the BCAA pattern with change in fasting glucose among boys, and with serum 
triglycerides among girls, based on results shown in Table 3 (Table 5),  Among boys, all 
metabolites were associated with a decrease in fasting glucose in boys, with the strongest 
association for propionylcarnitine (β= -4.38, 95% CI: -7.79, -0.97 mg/dL per 1 z-score) and 
isobutyrylcarnitine (β=-3.54, 95% CI: -6.18, -0.90 mg/dL per 1 z-score). Among girls, the 
majority of compounds exhibited a positive relationship with change in triglycerides, with the 
strongest association detected for kynurenine (β=3.65, 95% CI: 0.10, 7.21 mg/dL per 1 z-score) 
and gamma-glutamylleucine (β=4.44, 95% CI: 1.10, 7.79 mg/dL per 1 z-score). 
 When testing for effect modification by pubertal status, we found evidence of an 
interaction with respect to SBP in boys, so we ran these models within strata of baseline pubertal 
status (Table 6). The BCAA pattern was inversely related to change in SBP in pre-pubertal boys 
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(n=79; Model 1: β=-0.86, 95% CI: -2.06, 0.33 mmHg per 1 unit BCAA score), but was 
positively associated with change in SBP in pubertal boys (n=19; Model 1: β=1.67, 95% CI:        
-0.82, 4.16 mmHg per 1 unit BCAA score). Further adjustment for baseline BMI percentile did 
not change these findings (pre-pubertal boys: β=-0.88, 95% CI: -2.09, 0.33; pubertal boys: 
β=2.48, 95% CI: -0.45, 5.40 mmHg per 1 unit BCAA score). We examined these relationships 
with individual metabolites, and identified associations with respect to tryptophan (β=2.59, 95% 
CI: 0.03, 5.15 mmHg per 1 z-score of the metabolite) and kynurenine (β=2.53, 95% CI: 0.51, 
4.55 mmHg per 1 metabolite z-score; Table 6). 
 Table 7 shows associations of metabolites in the androgen pattern with the change in 
leptin and CRP in girls (outcomes selected based on findings from Table 4). All individual 
metabolites were consistently inversely associated with change in leptin, with the strongest 
associations for 4-androsten-3beta,17beta-diol disulfate 2 (β=-1.78, 95% CI: -3.35, -0.20 ng/dL 
per 1 z-score) and pregn steroid monosulfate (β=-2.50, 95% CI: -4.87, -0.13 ng/dL per 1 z-
score). The majority of metabolites were positively associated with change in CRP, but none of 
the estimates were statistically significant.  
 None of the relationships assessed differed by baseline BMI percentile. In sensitivity 
analyses, we evaluated the impact of adjustment for background characteristics associated with 
the metabolite patterns in bivariate analysis – namely, pre-pregnancy BMI, and annual household 
income, and child’s race/ethnicity. Inclusion of these variables did not change the results, so we 
did not include them for the sake of parsimony. An assessment of background characteristics of 
each of the subsamples analyzed in multivariable analyses yielded no notable differences, thus 
indicating that risk of bias due to missing data is likely low (Table S1).  
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DISCUSSION 
 In this prospective study of 253 children 6-10 years of age at baseline, we examined 
associations of two previously-derived metabolite patterns – a branched chain amino acid 
(BCAA) metabolite pattern and an androgen hormone pattern (8) – with change in conventional 
metabolic biomarkers during ~5 years of follow-up. Counter to findings from adults (5, 24), the 
BCAA pattern was not associated with worsening metabolic health in this cohort of adolescents, 
as the majority of the relationships we examined were null. However, we did find an inverse 
association of the BCAA pattern with change in fasting glucose in boys, and a direct relation of 
this pattern with change in serum triglycerides in girls. The androgen hormone pattern, which, to 
our knowledge has not been evaluated in relation to metabolic risk in other populations, was 
related to decreased leptin and increased CRP during follow-up in girls. 
BCAA metabolite pattern 
During mid-childhood, the BCAA pattern was associated with obesity, as well as higher 
fasting glucose, insulin, HOMA-IR, leptin, CRP, and IL-6. When we examined associations with 
change in the biomarkers during follow-up, the majority of estimates were null, with the 
exceptions of an inverse relationship between the BCAA pattern and fasting glucose in boys, and 
a direct association with serum triglycerides in girls.  
BCAA pattern and change in fasting glucose in boys 
This finding was counter to what we expected based on findings in adults (5, 24), as well 
as two prospective studies in adolescents that did not account for glycemia at baseline (9, 10). 
However, our findings align with results of two cross-sectional analyses in similarly-aged youth. 
In a study of 139 adolescents ~13 years of age, Michaliszyn et al. found that several compounds 
Page 14 of 41
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
15 
 
in the BCAA pattern, including leucine, isoleucine, valine, phenylalanine, and 
propionylcarnitine, were associated with higher insulin sensitivity (7). In the same population, 
Mihalik et al. unveiled evidence that these metabolites were also associated with enhanced fatty 
acid oxidation (6). The investigators hypothesized that the discrepancy in direction of association 
in adults vs. adolescents may be due to an adaptive increase in mitochondrial function (and 
accordingly, an improvement in glycemia) during early life that eventually wanes with age and 
continued metabolic dysregulation (25). Another explanation for our finding relates to the 
nutrient-signaling properties of BCAAs. For example, leucine activates the mammalian target of 
rapamycin (mTOR), a nutrient sensor involved in the neurocircuitry of energy balance, food 
intake, and glycemic regulation (26), that has been shown to improve glucose tolerance in mice 
(27). The fact that we observed positive, albeit non-significant, associations with fasting insulin 
and HOMA-IR supports this mechanism.  
Of note, a recent study of 16 children 8-13 years of age who were obese but non-diabetic 
at baseline found that although circulating BCAAs were associated with worse glycemia 
throughout the course of an oral glucose tolerance test (OGTT) at baseline, these metabolites 
were not associated with glucose control or indices of insulin secretion/sensitivity over 2.3 years 
of follow-up (11).  These findings are generally in line with those of the present analysis, given 
our predominantly null results with respect to other glycemia biomarkers (fasting insulin, 
HOMA-IR). 
 When we examined associations of individual metabolites within the BCAA pattern with 
glucose during follow-up in boys, we found that propionylcarnitine and isobutyrylcarnitine were 
the strongest determinants of decreasing glucose during follow-up. Both compounds are 
downstream intermediates of BCAA catabolism, and the latter of which (isobutyrylcarnitine) is 
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also product of acyl coenzyme A (acyl-CoA) beta oxidation – a process that feeds into the citric 
acid cycle for energy production (28). Although we were not able to locate any published studies 
on isobutyrylcarnitine in relation to glycemia, a pilot trial of 24 patients who were obese and had 
type 2 diabetes found that intravenous administration of propionylcarnitine improved glycemic 
control (29). Proposed mechanisms include propionylcarnitine’s involvement in muscle 
metabolism, endothelial function, and carbohydrate oxidation (30, 31). 
 The BCAA pattern was also associated with increasing SBP among pubertal, but not pre-
pubertal boys. Specific metabolites driving this relationship were tryptophan and its downstream 
metabolite, kynurenine. These results support findings of Wolf et al., who demonstrated that 
intraperitoneal tryptophan administration reduced blood pressure in hypertensive rodents, but 
increased blood pressure in normotensive animals (32). The investigators speculated that the 
duality of tryptophan’s effect on blood pressure is complex and regulated by numerous 
physiological processes involved in control of blood pressure, like brain monoamines and 
catecholamines (32). In the present study population, the majority of children were normotensive 
at baseline (98.8%), therefore the positive relationship between tryptophan and SBP corroborates 
results from rodent models. The fact that this relationship was only observed among pubertal 
boys may reflect the sex-specific differences in blood pressure change during puberty (33).  
BCAA pattern and change in serum triglycerides in girls 
 In girls, a higher score for the BCAA pattern was associated with increased serum 
triglycerides. When we examined component metabolites of the BCAA pattern, we detected the 
strongest relations with respect to kynurenine and gamma-glutamylleucine.  
Page 16 of 41
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
17 
 
Although there have not been any publications specifically relating kynurenine to 
triglycerides, growing evidence suggests that deregulation of the tryptophan-to-kynurenine 
pathway is involved in atherosclerotic cardiovascular disease, possibly through perturbations in 
immune pathways (34). Despite an equally scanty literature on gamma-glutamylleucine in 
relation to lipid profile, the positive association between this compound and triglycerides may 
reflect defective hepatic lipid metabolism, as gamma-glutamylleucine has been associated with 
non-alcoholic fatty liver disease – a condition characterized by accumulation of triglycerides in 
the liver, and elevated circulating triglycerides (35, 36). Because blood lipid levels exhibit high 
within-person variability until after puberty (37), whether or not these compounds serve as early 
indicators of dyslipidemia deserves further investigation beyond adolescence.  
 
Androgen hormone metabolite pattern 
 During mid-childhood, the androgen hormone metabolite pattern, which we speculated 
was an indicator of pubarchal/pubertal advancement, was associated with higher HOMA-IR, and 
marginally higher serum triglycerides, leptin, and IL-6, and lower adiponectin (8). When we 
examined these relationships prospectively, we found that this metabolite pattern corresponded 
with a decrease in leptin and an increase in CRP in girls. The androgen hormone pattern was not 
associated with change in any of the biomarkers in boys. 
Androgen pattern and change in leptin in girls 
A higher score for this pattern at baseline corresponded with a decrease in leptin in girls, 
which was unexpected given that this metabolite pattern is associated with more advanced 
pubarchal/pubertal status at baseline (8) and the fact that leptin levels increase throughout 
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adolescence in females (38, 39). While this finding could be due to variability in tempo of 
maturation during follow-up (a variable that we did not control for because it could be on the 
causal pathway), additional studies are warranted to confirm our results.  When we examined 
associations with specific metabolites, we detected the strongest relations with the testosterone 
precursor 4-androsten-3beta,17beta-diol disulfate 1, and pregn steroid monosulfate which is an 
intermediate in the steroidogenesis of androgen hormones from cholesterol.   
Androgen pattern and change in CRP in girls 
The androgen hormone pattern, but not the individual metabolites, was also related to 
increasing CRP in girls. This finding aligns with published data on the precipitous increase in 
CRP in females, but not males, during adolescence – particularly during the later stages of 
puberty (40). Future investigations are warranted to ascertain whether this relationship persists 
beyond puberty. 
Strengths & weaknesses  
This study has several weaknesses. First, assessment of plasma metabolites at a single 
point in time precludes our ability to infer on upregulation vs. downregulation of specific 
pathways. Second, we did not implement challenge testing (e.g., OGTT), nor did we measure 
glycated hemoglobin, and thus were not able to evaluate the entire range of glycemia. Third, use 
of complete case analysis is subject to missing data bias; however, a comparison of background 
characteristics among each of the subsamples provided no indication of differences in 
background characteristics of participants within the subsamples. Fourth, there may be residual 
confounding from variation in the tempo of sexual maturation during follow-up. Finally, as is the 
case with most analyses of high-dimensional ‘omics data, we cannot rule out the possibility of 
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false positive associations, although we aimed to examine and compare associations (many of 
which are on correlated biochemical pathways) in order to gain insight on etiology, rather than to 
predict outcomes.  
Strengths of this investigation include our ability to examine the relationship of two 
metabolite patterns with prospective change in multiple metabolic biomarkers in a cohort of 
multi-ethnic youth. Each of these elements are key improvements upon published studies, which 
have mostly been cross-sectional (6-9), of smaller sample size and shorter duration of follow-up 
(n=17 for 18 months (9); n=102 for 2 years (10)), and conducted in rather specific populations 
(e.g., Korean boys (10)).  
Conclusions 
We detected sex-specific associations of the BCAA and androgen hormone metabolite 
patterns with change in conventional metabolic biomarkers during ~5 years of follow-up in this 
population of youth aged 6-10 years at baseline. Specifically, the BCAA pattern corresponded 
with decreasing fasting glucose in boys, and increasing serum triglycerides in girls. However, 
given that the majority of associations were null (which may be an artefact of small sample 
sizes), the BCAA metabolite pattern does not appear to be an indicator of worsening metabolic 
health during early adolescence. The androgen hormone pattern – which, to our knowledge, has 
not been reported in other populations – was associated with a decrease in leptin and an increase 
in CRP in girls; these finding are likely related to timing of sexual maturation.  
Given that puberty is a time of rapid physiological change, future studies are required to 
evaluate these relationships beyond the adolescence, and to interrogate the capacity of the these 
metabolite patterns to predict metabolic disease progression beyond that of conventional 
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biomarkers. Nevertheless, given that many metabolic risk factors, including blood pressure (41, 
42), lipid profile (42, 43), and glycemia (42), track from late childhood/early adolescence into 
adulthood, a better understanding of early biomarkers of metabolic risk is a crucial step towards 
identification of targets for primary prevention.   
Page 20 of 41
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
21 
 
ACKNOWLEDGEMENTS: We are indebted to past and present Project Viva participants and 
research assistants.  
Page 21 of 41
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
22 
 
REFERENCES 
1. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. 
Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. J 
Am Med Assoc. 2014;311(17):1778-86. 
2. Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, et al. A clinical trial to 
maintain glycemic control in youth with type 2 diabetes. New Engl J Med. 2012;366(24):2247-
56. 
3. Institute of Medicine (US) Committee on Prevention of Obesity in Children and Youth. 
Preventing Childhood Obesity: Health in the Balance. Washington, D.C.; 2005. 
4. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-
chain amino acid-related metabolic signature that differentiates obese and lean humans and 
contributes to insulin resistance. Cell Metab. 2009;9(4):311-26. 
5. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite 
profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448-53. 
6. Mihalik SJ, Michaliszyn SF, de las Heras J, Bacha F, Lee S, Chace DH, et al. 
Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 
diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care. 2012;35(3):605-11. 
7. Michaliszyn SF, Sjaarda LA, Mihalik SJ, Lee S, Bacha F, Chace DH, et al. Metabolomic 
profiling of amino acids and beta-cell function relative to insulin sensitivity in youth. J Clin 
Endocrinol Metab. 2012;97(11):E2119-24. 
8. Perng W, Gillman MW, Fleisch AF, Michalek RD, Watkins SM, Isganaitis E, et al. 
Metabolomic profiles and childhood obesity. Obesity. 2014;22(12):2570-8. 
Page 22 of 41
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
23 
 
9. McCormack SE, Shaham O, McCarthy MA, Deik AA, Wang TJ, Gerszten RE, et al. 
Circulating branched-chain amino acid concentrations are associated with obesity and future 
insulin resistance in children and adolescents. Pediatric Obes. 2013;8(1):52-61. 
10. Lee A, Jang HB, Ra M, Choi Y, Lee H-J, Park JY, et al. Prediction of future risk of 
insulin resistance and metabolic syndrome based on Korean boy's metabolite profiling. Obes Res 
Clin Pract. 2015;9(4):336-45. 
11. Trico D, Prinsen H, Giannini C, de Graaf R, Juchem C, Li F, et al. Elevated alpha-
Hydroxybutyrate and Branched-Chain Amino Acid Levels Predict Deterioration of Glycemic 
Control in Adolescents. J Clin Endocrinol Metab. 2017;102(7):2473-81. 
12. Oken E, Baccarelli AA, Gold DR, Kleinman KP, Litonjua AA, De Meo E, et al. Cohort 
profile: Project Viva. Int J Epidemiol. 2015;44(1):37-48.. 
13. Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, et al. alpha-
hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a 
nondiabetic population. PloS one. 2010;5(5):e10883. 
14. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, et al. An atlas of 
genetic influences on human blood metabolites. Nat Genet. 2014;46(6):543-50. 
15. Evans A, Bridgetwater B, Liu Q, Mitchell M, Robinson R, Dai H, et al. High resolution 
mass spectrometry improves data quantity and quality as compared to unit mass resolution mass 
spectrometry in high-throughput profiling metabolomics. Metabolomics. 2014;4(132). 
16. Viitasalo A, Lakka TA, Laaksonen DE, Savonen K, Lakka HM, Hassinen M, et al. 
Validation of metabolic syndrome score by confirmatory factor analysis in children and adults 
and prediction of cardiometabolic outcomes in adults. Diabetologia. 2014;57(5):940-9. 
17. Conwell LS, Trost SG, Brown WJ, Batch JA. Indexes of insulin resistance and secretion 
in obese children and adolescents: a validation study. Diabetes Care. 2004;27(2):314-9. 
Page 23 of 41
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
24 
 
18. George L, Bacha F, Lee S, Tfayli H, Andreatta E, Arslanian S. Surrogate estimates of 
insulin sensitivity in obese youth along the spectrum of glucose tolerance from normal to 
prediabetes to diabetes. J Clin Endocrinol Metab. 2011;96(7):2136-45. 
19. Gungor N, Saad R, Janosky J, Arslanian S. Validation of surrogate estimates of insulin 
sensitivity and insulin secretion in children and adolescents. J Pediatr. 2004;144(1):47-55. 
20. Bridges KG, Jarrett T, Thorpe A, Baus A, Cochran J. Use of the triglyceride to HDL 
cholesterol ratio for assessing insulin sensitivity in overweight and obese children in rural 
Appalachia. J Pediatr Endocrinol Metab. 2016;29(2):153-6. 
21. Barker DJ, Bagby SP. Developmental antecedents of cardiovascular disease: a historical 
perspective. J Am Soc Nephrol. 2005;16(9):2537-44. 
22. Sun SS, Liang R, Huang TTK, Daniels SR, Arslanian S, Liu K, et al. Childhood Obesity 
Predicts Adult Metabolic Syndrome: The Fels Longitudinal Study. J Pediatr. 2008;152(2):191-
200.e1. 
23. Tu YK, West R, Ellison GT, Gilthorpe MS. Why evidence for the fetal origins of adult 
disease might be a statistical artifact: the "reversal paradox" for the relation between birth weight 
and blood pressure in later life. Am J Epidemiol. 2005;161(1):27-32. 
24. Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, et al. Novel biomarkers 
for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615. 
25. Lenaers E, De Feyter HM, Hoeks J, Schrauwen P, Schaart G, Nabben M, et al. 
Adaptations in mitochondrial function parallel, but fail to rescue, the transition to severe 
hyperglycemia and hyperinsulinemia: a study in Zucker diabetic fatty rats. Obesity. 
2010;18(6):1100-7. 
26. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, et al. Hypothalamic 
mTOR signaling regulates food intake. Science. 2006;312(5775):927-30. 
Page 24 of 41
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
25 
 
27. Macotela Y, Emanuelli B, Bång AM, Espinoza DO, Boucher J, Beebe K, et al. Dietary 
Leucine - An Environmental Modifier of Insulin Resistance Acting on Multiple Levels of 
Metabolism. PloS one. 2011;6(6):e21187. 
28. Pratt CW, Cornely K. Essential biochemistry: John Wiley & Sons, Inc.; 2004. 
29. Ragozzino G, Mattera E, Madrid E, Salomone P, Fasano C, Gioia F, et al. Effects of 
propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a 
pilot trial. Drugs in R&D. 2004;5(4):185-90. 
30. Cipolla MJ, Nicoloff A, Rebello T, Amato A, Porter JM. Propionyl-L-carnitine dilates 
human subcutaneous arteries through an endothelium-dependent mechanism. J Vasc Surg. 
1999;29(6):1097-103. 
31. Barker GA, Green S, Askew CD, Green AA, Walker PJ. Effect of propionyl-L-carnitine 
on exercise performance in peripheral arterial disease. Med Sci Sports Exerc. 2001;33(9):1415-
22. 
32. Wolf WA, Kuhn DM. Effects of L-tryptophan on blood pressure in normotensive and 
hypertensive rats. Journal of Pharmacology and Experimental Therapeutics. 1984;230(2):324. 
33. Shankar RR, Eckert GJ, Saha C, Tu W, Pratt JH. The change in blood pressure during 
pubertal growth. J Clin Endocrinol Metab. 2005;90(1):163-7. 
34. Wang Q, Liu D, Song P, Zou M-H. Deregulated tryptophan-kynurenine pathway is linked 
to inflammation, oxidative stress, and immune activation pathway in cardiovascular diseases. 
Front Biosci. 2015;20:1116-43. 
35. Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min H-K, et al. The Plasma 
Lipidomic Signature of Nonalcoholic Steatohepatitis. Hepatology. 2009;50(6):1827-38. 
36. Zhang J, Zhao Y, Xu C, Hong Y, Lu H, Wu J, et al. Association between serum free fatty 
acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci Rep. 2014;4:5832. 
Page 25 of 41
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
26 
 
37. Haney EM, Huffman LH, Bougatsos Cea. Screening for Lipid Disorders in Children and 
Adolescents Rockville (MD): Agency for Healthcare Research and Quality (US)2007 [Available 
from: http://www.ncbi.nlm.nih.gov/books/NBK33489/. 
38. Apter D. The role of leptin in female adolescence. Ann N Y Acad Sci. 2003;997:64-76. 
39. Clayton P, Trueman J. Leptin and puberty. Arch Dis Child. 2000;83(1):1-4. 
40. Shanahan L, Copeland WE, Worthman CM, Erkanli A, Angold A, Costello EJ. Sex-
differentiated changes in C-reactive protein from ages 9 to 21: the contributions of BMI and 
physical/sexual maturation. Psychoneuroendocrinology. 2013;38(10):2209-17. 
41. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic 
review and meta-regression analysis. Circulation. 2008;117(25):3171-80. 
42. Bao W, Srinivasan SR, Wattigney WA, Berenson GS. Persistence of multiple 
cardiovascular risk clustering related to syndrome X from childhood to young adulthood. The 
Bogalusa Heart Study. Arch Intern Med. 1994;154(16):1842-7. 
43. Webber LS, Srinivasan SR, Wattigney WA, Berenson GS. Tracking of serum lipids and 
lipoproteins from childhood to adulthood. The Bogalusa Heart Study. Am J Epidemiol. 
1991;133(9):884-99. 
Page 26 of 41
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
This article is protected by copyright. All rights reserved.
Au
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
27 
Page 27 of 41
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901
Obesity
56
57
58
59
60
This article is protected by copyright. All rights reserved.
Au
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
Table 1 Descriptive statistics (mean ± SD) for the branched chain amino acid (BCAA) factor score, age, and metabolic biomarkers of 104 boys and 109 
girls in the Project Viva cohort during mid-childhood (baseline) and the early teens (follow-up). 
N 
Boys (n = 104) 
P
a
 N 
Girls  (n = 109) 
P
a
 
Baseline Follow-up Baseline Follow-up 
Factor 4 (BCAA pattern) -0.02 ± 1.51 0.02 ± 1.51 
Factor 9 (Androgen pattern) -0.02 ± 1.56 -0.02 ± 1.56 
Age (years) 104 7.9 ± 0.8 13.0 ± 0.7 0.0007 109 7.9 ± 0.8 13.1 ± 0.7 
BMI (kg/m2) 104 17.8 ± 3.3 21.3 ± 5.0 <0.0001 109 19.2 ± 4.2 23.5 ± 5.7 <0.0001 
BMI percentileb 104 66.7 ± 27.3 63.2 ± 30.7 0.04 109 71.0 ± 31.0 72.3 ± 28.7 0.37 
Insulin (µU/mL) 78 8.1 ± 5.8 17.4 ± 14.8 <0.0001 85 11.2 ± 7.6 18.7 ± 11.6 <0.0001 
Glucose (mg/dL) 66 102.0 ± 17.8 96.2 ± 27.5 0.08 79 96.0 ± 14.4 93.7 ± 14.5 0.33 
HOMA-IR 63 2.1 ± 2.0 3.9 ± 3.7 0.0007 77 2.5 ± 1.6 4.3 ± 3.1 <0.0001 
Leptin (ng/mL) 81 5.9 ± 7.4 9.9 ± 14.6 0.001 86 10.2 ± 10.9 22.3 ± 18.7 <0.0001 
Adiponectin (ng/mL) 81 14.7 ± 8.3 6.0 ± 2.6 <0.0001 86 15.5 ± 10.5 6.3 ± 2.8 <0.0001 
CRP (mg/L) 82 0.97 ± 2.90 0.93 ± 1.97 0.88 83 1.73 ± 4.98 1.19 ± 2.08 0.28 
IL-6 (pg/mL) 80 0.92 ± 1.10 1.13 ± 1.45 0.25 86 1.15 ± 1.55 1.44 ± 2.03 0.24 
Total cholesterol (mg/dL) 83 163.5 ± 26.9 155.3 ± 29.4 0.005 87 164.6 ± 22.5 157.2 ± 27.7 0.003 
HDL (mg/dL) 83 59.9 ± 22.7 55.4 ± 15.3 0.0006 87 55.5 ± 12.3 55.1 ± 13.4 0.74 
LDL (mg/dL) 83 92.3 ± 25.0 86.2 ± 24.5 0.02 87 97.0 ± 20.7 89.2 ± 22.6 0.0001 
Triglycerides (mg/dL) 83 56.9 ± 22.7 68.7 ± 31.2 0.0008 87 60.3 ± 25.5 64.2 ± 29.5 0.26 
SBP (mmHg) 103 96.0 ± 9.0 110.0 ± 8.9 <0.0001 108 95.8 ± 9.0 105.8 ± 9.4 <0.0001 
DBP (mmHg) 103 54.9 ± 5.3 61.3 ± 7.4 <0.0001 108 54.3 ± 5.4 62.7 ± 6.7 <0.0001 
MetS z-scorec 62 0.17 ± 0.61 0.21 ± 0.72 0.57   76 0.17 ± 0.68 0.05 ± 0.63 0.12 
HOMA-IR: homeostatic model assessment of insulin resistance; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SBP: systolic blood pressure; DBP: 
diastolic blood pressure; MetS z-score: metabolic syndrome z-score; CRP: c-reactive protein; IL-6: interleukin-6; BMI: body mass index. 
a From a paired t-test. 
b According to the CDC growth reference for children 2-19 years of age. 
c Calculated as the average of 5 internally-standardized sex-specific z-scores for inverted HDL, waist circumference, ln-transformed HOMA-IR, ln-transformed 
triglycerides, and SBP. 
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N 
BCAA pattern 
factor score 
P
a
 
Androgen pattern 
factor score 
P
a
 
Maternal & perinatal characteristics 
Annual household income 
 
0.05 0.02 
≤$70 k 81 0.25 ± 1.49 0.27 ± 1.69 
>$70 k                                        115 -0.17 ± 1.57 -0.25 ± 1.42 
Smoking habits 
 
0.21 0.23 
Never 141 -0.15 ± 1.56 0.09 ± 1.55 
Former 47 0.20 ± 1.43 -0.36 ± 1.62 
Smoked in early pregnancy 25 0.29 ± 1.27 0.04 ± 1.52 
Pre-pregnancy BMI
b
  0.008 0.25 
Normal weight 114 -0.20 ± 1.54 -0.05 ± 1.56 
Overweight 53 -0.11 ± 1.31 -0.28 ± 1.41 
Obese 46 0.53 ± 1.53 0.36 ± 1.71 
Gestational weight gain 
 
0.18 0.27 
Inadequate 23 -0.15 ± 1.95 -0.31 ± 1.30 
Adequate 65 -0.24 ± 1.59 -0.08 ± 1.47 
Excessive 125 0.12 ± 1.36 0.07 ± 1.66 
Gestational glucose tolerance 
 
0.68 0.53 
Normoglycemic 163 0.00 ± 1.52 -0.06 ± 1.61 
Isolated hyperglycemia 28 -0.18 ± 1.44 0.18 ± 1.20 
Impaired glucose tolerance 6 1.25 ± 1.28 -0.85 ± 2.21 
Gestational diabetes 17 -0.39 ± 1.42 0.32 ± 1.41 
Duration of any breastfeeding 
 
0.52 0.20 
<1 months 33 -0.05 ± 1.58 0.30 ± 1.34 
1-<7 months 71 0.27 ± 1.32 -0.20 ± 1.80 
7-<12 months 40 -0.74 ± 1.53 0.25 ± 1.60 
≥12 months 47 0.11 ± 1.48 -0.38 ± 1.31 
Child's characteristics at baseline (mid-childhood visit) 
Age 
 
0.73 0.03 
<7 years 12 -0.14 ± 1.18 -0.39 ± 1.49 
7 to <8 years 129 -0.03 ± 1.56 -0.16 ± 1.41 
≥8 years 72 0.02 ± 1.47 0.30 ± 1.79 
Race/ethnicity 
 
0.76 0.003 
White 125 -0.03 ± 1.51 -0.25 ± 1.49 
Black 46 0.15 ± 1.36 0.71 ± 1.77 
Hispanic 15 -0.27 ± 1.55 0.15 ± 1.29 
Other  28 -0.13 ± 1.72 -0.27 ± 1.36 
Sex 
 
0.36 0.80 
Male 104 -0.12 ± 1.49 -0.05 ± 1.60 
Female 109 0.07 ± 1.52 0.01 ± 1.53 
Weight status
c
 <0.0001 0.0004 
Normal weight 122 -0.48 ± 1.46 -0.29 ± 1.44 
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Pubertal status 0.93 0.01 
Pre-pubertal 144 -0.02 ± 1.51 -0.22 ± 1.53 
Pubertal 60 0.00 ± 1.48   0.38 ± 1.56   
a Represents a test for linear trend for ordinal variables, and a type 3 test for difference for dichotomous 
and categorical (race/ethnicity and smoking habits) 
b According to the World Health Organization (WHO) and Centers for Disease Control and Prevention 
(CDC) adult weight status classification. "Normal weight" includes 4 women classified as "underweight." 
c According to the CDC 2000 age- and sex-specific reference data. "Normal weight" includes 4 children 
classified as underweight (BMI <5th percentile). 
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Table 3 Associations of the BCAA metabolite pattern factor score with change in metabolic biomarkers between mid-childhood (~7 years) and the early teens (~12 
years) among boys and girls in Project Viva 
β (95% CI) per 1 unit  BCAA pattern factor score
a
 
Boys (n = 104) Girls (n = 109) 
Unadjusted Model 1 Model 2 Unadjusted Model 1 Model 2 
Change in metabolic biomarkers 
Insulin (µU/mL) -0.26 (-2.40, 1.88) 1.64 (-0.35, 3.64) 1.51 (-0.49, 3.51) 0.57 (-1.26, 2.41) 1.04 (-0.67, 2.75) 0.59 (-1.14, 2.32) 
Glucose (mg/dL) -3.42 (-7.63, 0.79) -4.70 (-8.47, -0.93) -4.97 (-8.83, -1.11) 2.58 (-0.69, 5.86) 2.12 (-0.22, 4.45) 1.60 (-0.78, 3.98) 
HOMA-IR -0.48 (-1.12, 0.15) 0.31 (-0.17, 0.79) 0.26 (-0.22, 0.73) 0.35 (-0.16, 0.85) 0.39 (-0.11, 0.89) 0.24 (-0.26, 0.75) 
Leptin (ng/mL) 0.53 (-0.99, 2.05) 0.23 (-1.34, 1.80) 0.06 (-1.54, 1.65) 0.23 (-2.21, 2.68) 0.35 (-2.18, 2.89) -1.04 (-3.39, 1.31) 
Adiponectin (ng/mL) -0.29 (-1.43, 0.84) -0.13 (-0.49, 0.23) -0.04 (-0.40, 0.33) -0.21 (-1.54, 1.11) -0.01 (-0.35, 0.33) 0.03 (-0.33, 0.38) 
CRP (mg/L) 0.07 (-0.23, 0.37) 0.03 (-0.17, 0.23) 0.03 (-0.17, 0.24) -0.16 (-0.82, 0.51) 0.07 (-0.21, 0.36) 0.09 (-0.21, 0.39) 
IL-6 (pg/mL) 0.15 (-0.08, 0.38) 0.13 (-0.08, 0.33) 0.11 (-0.11, 0.32) -0.08 (-0.40, 0.24) -0.04 (-0.34, 0.25) 0.05 (-0.25, 0.35) 
Total cholesterol (mg/dL) -2.29 (-5.80, 1.22) -2.78 (-5.96, 0.39) -2.87 (-6.13, 0.38) -0.94 (-4.13, 2.25) -0.99 (-4.16, 2.19) -0.97 (-4.30, 2.35) 
HDL (mg/dL) -1.06 (-2.62, 0.51) -1.21 (-2.71, 0.30) -1.02 (-2.56, 0.51) 0.62 (-0.91, 2.15) 0.06 (-1.44, 1.55) 0.49 (-1.02, 1.99) 
LDL (mg/dL) -1.54 (-4.61, 1.53) -1.85 (-4.56, 0.86) -2.15 (-4.92, 0.61) -2.00 (-4.54, 0.54) -1.61 (-4.14, 0.92) -1.99 (-4.62, 0.65) 
Triglycerides (mg/dL) 1.55 (-2.70, 5.79) 1.40 (-2.70, 5.49) 1.13 (-3.07, 5.33) 2.19 (-2.31, 6.69) 4.38 (0.40, 8.37) 3.99 (-0.13, 8.11) 
SBP (mmHg) -0.96 (-2.27, 0.35) -0.49 (-1.58, 0.60) -0.51 (-1.63, 0.62) 0.33 (-0.95, 1.62) 0.87 (-0.24, 1.98) 1.03 (-0.14, 2.20) 
DBP (mmHg) 0.28 (-0.68, 1.24) 0.21 (-0.72, 1.14) -0.03 (-0.98, 0.92) 0.47 (-0.37, 1.32) 0.46 (-0.36, 1.29) 0.56 (-0.30, 1.42) 
MetS z-scoreb -0.03 (-0.12, 0.07) 0.01 (-0.08, 0.11) 0.00 (-0.10, 0.09)   0.02 (-0.08, 0.13) 0.06 (-0.02, 0.15) 0.04 (-0.04, 0.12) 
a Model 1: Estimates are adjusted for pubertal status and the biomarker of interest at the mid-childhood visit, and age at mid-childhood and early teen visits. Model 2: Model 1 + BMI 
percentile at baseline. Bolded values indicate statistical significance at alpha <0.05. 
b Calculated as the average of 5 internally-standardized sex-specific z-scores for inverted HDL, waist circumference, ln-transformed HOMA-IR, ln-transformed triglycerides, and 
SBP. 
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Table 4 Associations of the androgen metabolite pattern factor score with change in metabolic biomarkers between mid-childhood (~7 years) and the early teens (~12 
years) among boys and girls in Project Viva 
β (95% CI) per 1 unit androgen  factor score
a
 
Boys (n = 104) Girls (n = 109) 
Unadjusted Model 1 Model 2 Unadjusted Model 1 Model 2 
Change in metabolic biomarkers 
Insulin (µU/mL) 1.04 (-1.09, 3.18) -0.19 (-2.15, 1.78) -0.48 (-2.47, 1.52) -1.35 (-2.96, 0.25) -1.12 (-2.66, 0.43) -1.14 (-2.64, 0.36) 
Glucose (mg/dL) 2.53 (-1.56, 6.62) 1.90 (-1.88, 5.68) 1.97 (-1.90, 5.85) -0.63 (-3.38, 2.13) 1.27 (-0.78, 3.32) 1.26 (-0.74, 3.25) 
HOMA-IR 0.43 (-0.17, 1.03) -0.09 (-0.52, 0.35) -0.21 (-0.65, 0.23) -0.32 (-0.73, 0.10) -0.22 (-0.66, 0.22) -0.21 (-0.64, 0.22) 
Leptin (ng/mL) 0.37 (-1.17, 1.91) -0.12 (-1.75, 1.52) -0.25 (-1.89, 1.39) -1.85 (-4.09, 0.40) -2.39 (-4.76, -0.02) -2.50 (-4.61, -0.39) 
Adiponectin (ng/mL) 0.46 (-0.68, 1.61) -0.01 (-0.38, 0.38) 0.07 (-0.31, 0.45) 1.04 (-0.18, 2.26) 0.00 (-0.32, 0.33) 0.01 (-0.32, 0.33) 
CRP (mg/L) -0.23 (-0.52, 0.05) 0.12 (-0.09, 0.32) 0.12 (-0.09, 0.33) 0.06 (-0.54, 0.66) 0.28 (0.03, 0.54) 0.28 (0.03, 0.54) 
IL-6 (pg/mL) 0.08 (-0.15, 0.31) 0.20 (-0.02, 0.41) 0.18 (-0.03, 0.40) 0.06 (-0.23, 0.36) 0.26 (-0.02, 0.55) 0.26 (-0.02, 0.54) 
Total cholesterol (mg/dL) -1.97 (-5.46, 1.52) -1.07 (-4.38, 2.24) -1.06 (-4.42, 2.30) -0.43 (-3.38, 2.52) -0.61 (-3.69, 2.46) -0.60 (-3.68, 2.48) 
HDL (mg/dL) -0.71 (-2.28, 0.85) -1.02 (-2.61, 0.58) -0.87 (-2.47, 0.72) 0.02 (-1.39, 1.44) -0.05 (-1.45, 1.36) 0.01 (-1.36, 1.39) 
LDL (mg/dL) -1.25 (-4.30, 1.81) 0.30 (-2.51, 3.11) 0.17 (-2.67, 3.01) -0.28 (-2.66, 2.09) -0.56 (-2.99, 1.87) -0.58 (-3.01, 1.84) 
Triglycerides (mg/dL) -0.07 (-4.30, 4.16) 0.12 (-4.09, 4.32) -0.12 (-4.37, 4.13) -0.85 (-5.02, 3.32) 1.73 (-2.11, 5.57) 1.71 (-2.10, 5.52) 
SBP (mmHg) -0.81 (-2.02, 0.40) 0.16 (-0.91, 1.22) 0.16 (-0.90, 1.22) -1.32 (-2.57, -0.07) -0.52 (-1.63, 0.59) -0.52 (-1.63, 0.59) 
DBP (mmHg) -0.17 (-1.05, 0.72) 0.19 (-0.71, 1.08) 0.06 (-0.83, 0.95) -0.17 (-1.01, 0.68) 0.14 (-0.68, 0.96) 0.15 (-0.67, 0.96) 
MetS z-scoreb -0.03 (-0.12, 0.06) -0.01 (-0.11, 0.08) -0.02 (-0.11, 0.07)   -0.10 (-0.18, -0.02) -0.04 (-0.12, 0.03) -0.04 (-0.11, 0.03) 
a Model 1: Estimates are adjusted for pubertal status and the biomarker of interest at the mid-childhood visit, and age at mid-childhood and early teen visits. Model 2: Model 1 + BMI 
percentile at baseline. Bolded values indicate statistical significance at alpha <0.05. 
b Calculated as the average of 5 internally-standardized sex-specific z-scores for inverted HDL, waist circumference, ln-transformed HOMA-IR, ln-transformed triglycerides, and 
SBP. 
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Table 5 Associations of metabolites within the BCAA pattern with change in fasting glucose in boys and change in 
serum triglycerides in girls. 
Factor 
loading 
Boys (n = 63) Girls (n = 83) 
β (95% CI) for change in 
fasting glucose (mg/dL)
a
 
β (95% CI) for change in 
serum triglycerides (mg/dL)
a
 
Valine 0.83 -2.91 (-6.83, 1.02) 1.72 (-1.88, 5.31) 
Leucine 0.76 -2.12 (-5.48, 1.24) 1.72 (-1.56, 4.99) 
Phenylalanine 0.72 -3.35 (-6.70, 0.01) 0.78 (-2.87, 4.44) 
Isoleucine 0.71 -3.10 (-7.07, 0.87) 2.26 (-1.16, 5.67) 
Propionylcarnitine (C3) 0.66 -4.38 (-7.79, -0.97) 2.01 (-2.31, 6.33) 
2-methylbutyrylcarnitine (C5) 0.63 -2.01 (-6.13, 2.10) 2.74 (-0.69, 6.16) 
Isovalerylcarnitine 0.30 -2.18 (-5.13, 0.76) -0.46 (-3.78, 2.86) 
Isobutyrylcarnitine 0.56 -3.54 (-6.18, -0.90) -0.22 (-3.40, 2.95) 
Tryptophan  0.54 -2.65 (-6.29, 0.98) -1.81 (-5.79, 2.16) 
3-methyl-2-oxovalerate (KMV) 0.52 -0.81 (-4.46, 2.85) 1.13 (-2.99, 5.25) 
Kynurenine 0.52 -1.39 (-5.06, 2.28) 3.65 (0.10, 7.21) 
Tyrosine 0.51 -3.70 (-8.35, 0.94) -2.38 (-6.14, 1.38) 
Gamma-glutamylleucine 0.51 -2.92 (-6.72, 0.88) 4.44 (1.10, 7.79) 
4-methyl-2-oxopentanoate (KIC) 0.51 -0.63 (-4.06, 2.80) -0.19 (-4.23, 3.85) 
a Estimates are adjusted for age, pubertal status, BMI percentile, and biomarker level at the mid-childhood visit, and age at the early 
teen visit. Bolded text indicates statistical significance at alpha<0.05. 
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Table 6 Associations of metabolites within the BCAA pattern with change (∆) in SBP in 98 boys, stratified by 
pubertal status at baseline (mid-childhood). 
Factor 
loading 
β (95% CI) for ∆ in SBP (mmHg)
a
 
Pre-pubertal (n= 79) Pubertal (n = 19) 
BCAA factor score 
 
-0.88 (-2.09, 0.33) 2.48 (-0.45, 5.40) 
 
Individual metabolites  
 
Valine 0.83 -0.44 (-1.40, 0.52) 0.91 (-1.77, 3.59) 
Leucine 0.76 -0.05 (-0.91, 0.81) 1.48 (-0.67, 3.63) 
Phenylalanine 0.72 0.19 (-0.70, 1.07) 1.79 (-0.23, 3.81) 
Isoleucine 0.71 -0.32 (-1.26, 0.62) 1.32 (-1.08, 3.73) 
Propionylcarnitine (C3) 0.66 -0.77 (-1.80, 0.26) -0.54 (-2.71, 1.41) 
2-methylbutyrylcarnitine (C5) 0.63 -0.17 (-1.32, 0.98) 0.65 (-2.19, 3.50) 
Isovalerylcarnitine 0.30 -0.17 (-1.14, 0.79) -0.25 (-1.71, 1.21) 
Isobutyrylcarnitine 0.56 -0.50 (-1.32, 0.33) -0.95 (-2.72, 0.82) 
Tryptophan  0.54 -0.80 (-1.64, 0.04) 2.59 (0.03, 5.15) 
3-methyl-2-oxovalerate (KMV) 0.52 -0.33 (-1.35, 0.68) 2.32 (-0.06, 4.71) 
Kynurenine 0.52 -0.38 (-1.39, 0.62) 2.53 (0.51, 4.55) 
Tyrosine 0.51 -0.21 (-1.44, 1.02) -0.17 (-3.12, 2.77) 
Gamma-glutamylleucine 0.51 -0.08 (-1.27, 1.10) 1.03 (-0.78, 2.84) 
4-methyl-2-oxopentanoate (KIC) 0.51 -0.04 (-1.02, 0.94) 2.31 (-0.08, 4.70) 
a Estimates are adjusted for age, pubertal status as an ordinal variable, BMI percentile, biomarker level at the mid-
childhood visit, and age at the early teen visit. Bolded text indicates statistical significance at alpha<0.05. 
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Table 7 Associations of metabolites within the androgen pattern with change in leptin and CRP in girls. 
Factor 
loading 
β (95% CI)
a
 
Change in leptin (ng/dL) Change in CRP (mg/dL) 
n = 82 n = 79 
4-Androsten-3beta,17beta-diol disulfate 1 0.86 -0.92 (-2.95, 1.11) 0.18 (-0.07, 0.42) 
Dehydroisoandrosterone sulfate (DHEA-S) 0.84 -1.68 (-4.47, 1.11) 0.05 (-0.29, 0.39) 
Epiandrosterone sulfate 0.79 -0.40 (-2.33, 1.52) 0.13 (-0.11, 0.37) 
Androsterone sulfate 0.79 -1.56 (-3.83, 0.71) 0.10 (-0.17, 0.37) 
4-androsten-3beta,17beta-diol disulfate 2* 0.78 -1.78 (-3.35, -0.20) 0.04 (-0.16, 0.23) 
Pregn steroid monosulfate* 0.76 -2.50 (-4.87, -0.13) 0.02 (-0.27, 0.31) 
Pregnen-diol disulfate* 0.70 -1.94 (-4.11, 0.23) -0.02 (-0.29, 0.25) 
Pregnenolone sulfate 0.65 -0.64 (-2.66, 1.39) 0.05 (-0.20, 0.30) 
Andro steroid monosulfate 2* 0.61 -1.09 (-3.14, 0.97) -0.02 (-0.28, 0.24) 
a Estimates are adjusted for age, pubertal status, BMI percentile, and biomarker level at the mid-childhood visit, and age at the early teen visit. 
Bolded text indicates statistical significance at alpha<0.05. Bolded text indicates statistical significance at alpha<0.05. 
* Indicates tier 2 identification in which no commercially available authentic standards could be found, however annotated based on accurate 
mass, spectral and chromatographic similarity to tier 1 identified compounds 
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Assays, laboratory techniques, and instrumentation for measurement of conventional 
metabolic biomarkers 
At both the mid-childhood and early teen visits, we used fasting blood to measure plasma 
glucose enzymatically, and insulin using an electrochemiluminescence immunoassay (Roche 
Diagnostics, Indianapolis, IN). Serum total cholesterol, triglycerides, and high-density 
lipoprotein (HDL) were measured enzymatically with correction for endogenous glycerol. We 
measured plasma leptin and adiponectin concentrations with a radioimmunoassay (Linco 
Research, St Charles, MO). We used an immunoturbidimetric high-sensitivity assay on a Hitachi 
911 analyzer to determine C-reactive protein (CRP) concentrations (Roche Diagnostics, 
Indianapolis, IN). Plasma interleukin-6 (IL-6) was measured by ultrasensitive enzyme-linked 
immunosorbent assay (ELISA).  
Assessment of covariates 
At enrollment, mothers reported their pre-pregnancy weight and height, from which we 
calculated pre-pregnancy BMI. We used standard criteria to categorize BMI as normal (defined 
as 18.5-<25 kg/m2, but we also included 4 women with BMI <18.5) overweight (25-<30 kg/m2), 
and obese (≥30 kg/m2) (1). Using interviews and questionnaires, we collected information on 
maternal race/ethnicity, age, household income; and child race/ethnicity. We determined 
gestational weight gain (GWG) as the difference between the last clinically-measured weight 
within 4 weeks prior to delivery and self-reported pre-pregnancy weight, and categorized it 
according to current IOM guidelines (2).  Obstetric clinicians screened women for gestational 
diabetes mellitus (GDM) at 26–28 weeks of gestation with a non-fasting 50-g oral glucose 
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on results of the 2-stage testing, we categorized women as having GDM, impaired glucose 
tolerance, isolated hyperglycemia, or normoglycemia (3). We obtained birth characteristics, 
including sex and delivery date, from medical records. Mothers reported on breastfeeding 
duration in postpartum questionnaires.  
At the mid-childhood and early teen visits, RAs measured children’s weight (kg) using an 
electronic scale (Tanita Corporation of America, Inc., Arlington Heights, IL) and height (cm) 
with a calibrated stadiometer (Shorr Productions, Olney, MD). We used these values to calculate 
BMI, standardized it as percentile using the Centers for Disease Control growth reference (4), 
and categorized participants as normal weight (5th to <85th percentile, but also included 4 
children with BMI <5th percentile), overweight (85th to <95th percentile), and obese (≥95th 
percentile). At the mid-childhood research visit, mothers reported on pubarchal/pubertal 
phenotype based on appearance of body hair, breast development for girls, and body hair, facial 
hair, and deepening of voice for boys on a scale of 1 (no development) to 4 (full development) 
(5). For the analysis, we combined the characteristics as an ordinal summary score of breast 
development and body hair for girls, and the mean of deepening of voice, facial hair, and body 
hair for boys for use as a covariate in multivariable models, as well as dichotomized as pre-
pubertal (puberty score=1) vs. pubertal (puberty score>1) for stratified analyses. 
Untargeted metabolomics profiling 
For untargeted metabolomics profiling, we sent fasting plasma samples collected at the 
mid-childhood visit to Metabolon Inc. (Durham, NC, USA). Samples were prepared using the 
automated MicroLab STAR® liquid handling machine from Hamilton Robotics, which employs 
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precipitate proteins fraction while allowing maximum recovery of small molecules. The extract 
was then divided into four fractions: one each for analysis on four different columns on ultrahigh 
performance liquid chromatography (UPLC)/MS/MS (2 for positive ions, 2 for negative ions) 
and mixed the samples for 5 minutes on a Geno/Grinder 2000 (Glen Mills, Inc.), followed by 
brief placement on a TurboVap® (Zymark) to remove the organic solvent.  
Next, sample extraction and ultrahigh performance liquid chromatography (UPLC) was 
carried out as previously described (6). The liquid chromatography (LC)/MS of the platform was 
based on a Waters ACQUITY UPLC and a Thermo-Finnigan linear trap quadrupole mass 
spectrometer, which consisted of an electrospray ionization source and linear ion-trap mass 
analyzer. The sample extract was reconstituted in acidic or basic LC-compatible solvents, each 
of which contained 8 or more injection standards at fixed concentrations to ensure injection and 
chromatographic consistency. One aliquot each was analyzed using a reverse-phase positive ion 
method for polar compounds, a reverse-phase positive ion method for lipid compounds, a 
reverse-phase negative ion method, and a negative ion method for hydrophilic compounds. The 
MS analysis alternated between MS and data-dependent MS/MS scans using dynamic exclusion.  
Raw data files are archived and extracted as described below. 
For quality assurance/quality control (QA/QC) purposes, extracts of a pool created from a 
small aliquot of the experimental samples and process blanks were included with each day’s 
analysis. The QC samples were spaced evenly among the injections and all experimental 
samples, and randomly distributed them throughout the run.  A selection of QC compounds were 
added to every sample for chromatographic alignment, including those under test. These 
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compounds. 
Finally, the raw data were extracted and compound peaks were identified using 
Metabolon’s hardware and software. Compounds were identified via comparison to library 
entries of purified standards or recurrent unknown entities.  More than 4000 commercially 
available purified standard compounds have been acquired and registered into Laboratory 
Information Management System (LIMS) for distribution to both the LC and GC platforms for 
determination of their analytical characteristics. 
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Table S1 Background characteristics of Project Viva participants within each of the analytical subsamples. 
 
Boys Girls 
Overall Table 5 Table 6 Overall Table 5 Table 7 Table 7 
  
(∆glucose) (∆SBP) 
 
(∆triglycerides) (∆leptin) (∆CRP) 
 
n = 104 n = 63  n = 98 n = 109 n = 83 n = 82 n = 79 
Maternal & perinatal characteristics 
Annual household income ≤$70 k 61.9% 70.5% 62.6% 55.6% 53.3% 52.7% 52.1% 
Smoked during pregnancy 10.6% 12.7% 11.2% 12.8% 13.3% 13.4% 13.9% 
Pre-pregnancy BMI (kg/m
2
) 25.3 ± 5.2 25.2 ± 5.5 25.2 ± 5.3 26.6 ± 6.5 26.5 ± 6.0 26.6 ± 6.0 26.6 ± 6.1 
Gestational weight gain
a
 
Inadequate 7.7% 9.5% 8.2% 13.8% 14.5% 14.6% 15.2% 
Adequate 28.9% 23.8% 25.5% 32.1% 32.5% 31.7% 32.9% 
Excessive 63.5% 66.7% 66.3% 54.1% 53.0% 53.7% 51.9% 
Gestational glucose tolerance 
Normoglycemic 79.8% 85.7% 81.6% 73.4% 74.7% 74.4% 73.4% 
Isolated hyperglycemia 9.6% 9.5% 9.2% 15.6% 16.9% 17.1% 17.7% 
Impaired glucose tolerance 2.9% 1.6% 3.1% 2.8% 2.4% 2.4% 2.5% 
Gestational diabetes 7.7% 3.2% 6.1% 8.3% 6.0% 6.1% 6.3% 
Duration of any breastfeeding 
<1 months 19.6% 18.3% 19.2% 14.9% 14.3% 14.5% 13.6% 
1-<7 months 33.0% 30.0% 34.0% 41.5% 42.9% 42.0% 42.4% 
7-<12 months 21.7% 23.3% 21.3% 20.2% 18.6% 18.8% 18.2% 
≥12 months 25.8% 28.3% 25.5% 23.4% 24.3% 24.6% 25.8% 
Child's characteristics at baseline 
Age (years) 7.9 ± 0.8 7.7 ± 0.7 7.9 ± 0.8 8.0 ± 0.8 8.0 ± 0.9 8.0 ± 0.9 8.0 ± 0.9 
Race/ethnicity 
White 61.5% 68.3% 63.3% 55.1% 53.0% 52.4% 53.2% 
Black 20.2% 15.9% 19.4% 22.9% 22.9% 23.2% 21.5% 
Hispanic 5.8% 4.8% 6.1% 8.3% 9.6% 9.8% 10.1% 
Other  12.5% 11.1% 11.2% 13.8% 14.5% 14.6% 15.2% 
BMI percentile
b
 66.6 ± 27.2 66.8 ± 28.8 66.1 ± 27.5 71.0 ± 31.0 72.2 ± 30.8 72.9 ± 30.3 72.9 ± 30.3 
Pubertal status 
Pre-pubertal 80.8% 82.5% 80.6% 61.0% 59.0% 58.5% 58.2% 
Pubertal 19.2% 17.5% 19.4%   39.1% 41.0% 41.5% 41.8% 
a According to the 2009 Institute of Medicine recommendations. 
b Age- and sex-specific BMI percentile based on CDC 2000 reference data. 
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